Search results
Results from the WOW.Com Content Network
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
DynCorp International Inc. (/ ˈ d aɪ n k ɔːr p /), [5] was an American private military contractor. [6] Starting as an aviation company, the company also provided flight operations support, training and mentoring, international development, intelligence training and support, contingency operations, security, and operations and maintenance of land vehicles. [7]
In the late 1940s, Henry Kempe suggested that the solution to the complications of the smallpox vaccine was to provide antibodies in the form of gamma globulin, a medical treatment known as passive immunity. [9] [10] Kempe noted that for some infants, the smallpox vaccine failed to "take". Kempe believed this failure might be due to the high ...
The Department of Defense's contract-awarding machine kicked into high gear Tuesday, as the Pentagon issued a total of 16 contracts worth a combined $2.7 billion. Among the larger contracts ...
Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...
The U.S. Department of Defense (DoD) has focused since at least 1998 on the development and application of vaccine-based biodefenses. In a July 2001 report commissioned by the DoD, the "DoD-critical products" were stated as vaccines against anthrax (AVA and Next Generation), smallpox , plague , tularemia , botulinum , ricin , and equine ...
Shares of the vaccine maker tumbled 17.1% to $65.88 at midday. The company expects sales between $2.5 billion and $3.5 billion in 2025, below analysts' forecast of $3.74 billion, according to LSEG ...
The vaccine produces a greater immune response than standard vaccine. According to the CDC, [1] "a study published in the New England Journal of Medicine [25] [in August, 2014] indicated that the high-dose vaccine was 24.2% more effective in preventing flu in adults 65 years of age and older relative to a standard-dose vaccine." The CDC ...